alcon

Shares of Novartis soared higher on Wednesday, after the Swiss drug maker finally obtained the remaining outstanding shares of Alcon for $12.9 billion.

Novartis is finally closing the deal on its pursuit of eye-care firm Alcon. But there's a twist: The price per share it's paying for Nestle's majority stake is far better than it's giving minority shareholders. And to add insult to injury, they face negative tax implications, too.

The following is a round-up of news likely to affect stock prices today: Novartis (NVS) has raised its stake in eye-care company Alcon (ACL) to 77% by buying Nestlé's majority stake for $28.1 billion, the Swiss drug giant said Monday, and has set its sights on acquiring the rest. Novartis...